Feuerstein's Biotech-Stock Mailbag

Welcome back and thanks for reading the last Biotech Mailbag for 2007. I'm going to put this column on a two-week hiatus after today and return rejuvenated in January.

Before we get to this week's emails, I want to express sincere gratitude to everyone who took time to send me comments and questions, praise and pans, over the past 12 months.

We covered a lot of ground this year, and I know I took a closer look at some biotech stocks that would have skipped right past me if your emails hadn't brought them to my attention. I learned a lot, and I hope you did too. (If you made some money as well, all the better.) ...